MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 ...

From theory to daily practice: how to avoid social traps, recognize biases, and engage in civil discussion even when opinions ...

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg Topline Data Remains on Track for Fourth Quarter 2026 CAMBRIDGE ...

Corxel Pharmaceuticals’ oral obesity candidate has succeeded in a Phase II trial in the US, teeing it up for a pivotal trial.

Vapes are one of the hottest product categories. With consumer expectations shifting towards consistency and cannabis moving towards medicalizing, innovation is a must.

Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding the use ...

Clinical guidelines support lower blood pressure targets and active volume removal to mitigate fluid overload in older sepsis ...

Learn how to optimize cement particle size analysis using the Bettersizer 2600 Plus to achieve faster testing.

Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...

In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to ...

Topline results from RISE3 are expected in H2 2026.

Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to ...